Report error Found 98 Enz. Inhib. hit(s) with all data for entry = 10455
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 7.17nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 14.8nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 58.6nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 85.1nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 181nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 255nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 294nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 31.3nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 6.72nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 15.9nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 6.28nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 27.4nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 10.2nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 3.70nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 3.71nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 13.4nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 23.4nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 28.7nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 11.2nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 38.7nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 1.5nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 97.6nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 5.83nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 76.5nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 89.1nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 0.770nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 0.960nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 11.9nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 0.960nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 450nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 1.33nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 1.79nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 0.870nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 94.7nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 0.700nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 1.36nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 2.14nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 43nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 0.810nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 1.61nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 0.530nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 11.2nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 4.13nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 1.55nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 3.83nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 2.79nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 2.03nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 1.42nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 3.02nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein [1-129]/Nuclear receptor corepressor 2 [1414-1429](Human)
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataKd: 111nMAssay Description:This assay was used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding...More data for this Ligand-Target Pair
